Skip to main
STRO

STRO Stock Forecast & Price Target

STRO Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sutro Biopharma is well-positioned in the ADC market with their innovative platform and promising candidate STRO-004, backed by strong partnerships and a focus on stable linker technology. The company's financials and cash position provide a solid base for future growth, making it an attractive investment opportunity.

Bears say

Sutro Biopharma is undergoing a pivot in its business strategy, focusing on its proprietary integrated cell-free protein synthesis platform, XpressCF, to develop novel treatments for cancer and autoimmune disorders. However, with a significant portion of its pipeline still in early stages of development and limited clinical data, there are concerns about the company's ability to successfully execute on its clinical programs. This, coupled with the fact that the company is heavily reliant on partnerships for revenue, indicates a high level of risk for investors. Additionally, Sutro's current valuation seems high based on traditional metrics, which suggests limited upside potential for the stock in the near term.

STRO has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sutro Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sutro Biopharma Inc (STRO) Forecast

Analysts have given STRO a Buy based on their latest research and market trends.

According to 9 analysts, STRO has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sutro Biopharma Inc (STRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.